Pharmacotherapy for nicotine dependence

Ca-A Cancer Journal for Clinicians

Volumn 55, Issue 5, 2005, Pages 281-299

  Henningfield, Jack E ^a,b   Fant, Reginald V ^a   Buchhalter, August R ^a   Stitzer, Maxine L ^b  

^a PINNEY ASSOCIATES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CLONIDINE; DOXEPIN; NICOTINE; NICOTINE GUM; NICOTINE QBETA; NICOTINE VACCINE; NICOTINIC AGENT; NON PRESCRIPTION DRUG; NORTRIPTYLINE; PLACEBO; RIMONABANT; TA NIC; UNCLASSIFIED DRUG; VACCINE; VARENICLINE;

ADDICTION; AEROSOL; BRADYCARDIA; CANCER MORTALITY; CHEWING GUM; CIGARETTE SMOKING; CLINICAL PRACTICE; CONSTIPATION; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; INHALER; INSOMNIA; LOZENGE; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEIZURE; SIDE EFFECT; SMOKING CESSATION; TABLET; TACHYCARDIA; TOBACCO; TOBACCO DEPENDENCE; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; VACCINATION; VAPOR; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 25444520229     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.55.5.281     Document Type: Review

References (125)

1. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2002. Morb Mortal Wkly Rep 2004;53:427-431.
2. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs-United States, 1995-1999. Morb Mortal Wkly Rep 2002; 51:300-303.
3. Mokdad AH, Mark JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004;291:1238-1245.
4. Windsor R, Oncken C, Henningfield J, et al. Behavioral and pharmacological treatment methods for pregnant smokers: issues for clinical practice. J Am Med Womens Assoc 2000;55:304-310.
5. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2004.
6. Gritz ER, Vidrine DJ, Lazev AB. Smoking cessation in cancer patients: Never too late to quit, in Given CW, Given B, Champion VL, et al. (eds). Evidence-based cancer care and prevention. New York: Springer Publishing Company; 2003:107-140.
7. Wald NJ, Watt HC. Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases. BMJ 1997;314:1860-1863.
8. Baker F, Ainsworth SR, Dye JT, et al. Health risks associated with cigar smoking. JAMA 2000; 284:735-740.
9. Connolly GN, Winn DM, Hecht SS, et al. The reemergence of smokeless tobacco. N Engl J Med 1986;314:1020-1027.
10. Hatsukami DK, Severson HH. Oral spit tobacco: addiction, prevention and treatment. Nicotine Tob Res 1999;1:21-44.
11. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2000.
12. US Department of Health and Human Services. Management of Nicotine Addiction. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2000.
13. World Health Organization. Policy Recommendations for Smoking Cessation and Treatment of Tobacco Dependence. Geneva, Switzerland: World Health Organization; 2003.
14. World Bank. Curbing the Epidemic: Governments and the Economics of Tobacco Control. Washington, DC: World Bank; 1999.
15. Benowitz NL, Porchet H, Sheiner L, Jacob III P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988;44:23-28.
16. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med 1994; 331:123-125.
17. US Department of Health and Human Services. The Health Consequences of Smoking: Nicotine Addiction, A Report of the Surgeon General. Washington, DC: US Government Printing Office; 1988.
18. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86: 1119-1127.
19. American Psychiatric Association. Diagnostic and statistical manual-IVTR. Washington, DC: American Psychiatric Association; 2000.
20. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995;333:1196-1203.
21. American Psychiatric Association. Practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 1996;153(10 Suppl):1-31.
22. Benowitz NL. Nicotine replacement therapy. What has been accomplished-can we do better? Drugs 1993;45:137-170.
23. Butschky MF, Bailey D, Henningfield JE, Pickworth WB. Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav 1995;50:91-96.
24. Finnegan JK, Larson PS, Haag HB. The role of nicotine in the cigarette habit. Science 1945; 102:94-96.
25. Rose JE, Behm FM, Westman EC, et al. Pharmacologic and sensorimotor components of satiation in cigarette smoking. Pharmacol Biochem Behav 2003:76:243-250.
26. Brauer LH, Behm FM, Lane JD, et al. Individual differences in smoking reward from denicotinized cigarettes. Nicotine Tob Res 2001;3: 101-109.
27. Snyder FR, Henningfield JE. Effects of nicotine administration following 12h of tobacco deprivation: assessment on computerized performance tasks. Psychopharmacology 1989;97:17-22.
28. Pickworth WB, Fant RV, Butschky MF, Henningfield JE. Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J Pharmacol Exp Ther 1996;279:450-456.
29. Shiffman S, Paty JA, Rohay JM, et al. The efficacy of computer-tailored smoking cessation material as a supplement to nicotine patch therapy. Drug Alcohol Depend 2001;64:35-46.
30. Sweeney CT, Fant RV, Fagerstrom KO, et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001;15:453-467.
31. Fagerstrom KO. Combined use of nicotine replacement products. Health Values 1994;18:15-20.
32. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592. Rockville, MD: Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service; 2004.
33. Benowitz NL. Clinical pharmacology of transdermal nicotine. Eur J Pharm Biophann 1995;41:168-174.
34. Gorsline J. Nicotine pharmacokinetics of four nicotine transdermal systems. Health Values 1993;17:20-24.
35. Fant RV, Henningfield JE, Shiftman S, et al. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 2000;67:479-482.
36. Shiffman S, Elash CA, Paton SM, et al. Comparative efficacy of 24-hour and 16-hour transdennal nicotine patches for relief of morning craving. Addiction 2000;95:1185-1195.
37. Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999;159:2033-2038.
38. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995;333:1196-1203.
39. Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue- elicited craving in cigarette smokers. J Consult Clin Psychol 2000;68:233-240.
40. Shiffman S, Engberg JB, Pary JA, et al. A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol 1997;106:104-116.
41. Shiffman S, Gnys M, Richards TJ, et al. Temptations to smoke after quitting: a comparison of lapsers and maintainers. Health Psychol 1996;15:455-461.
42. Shiffman S, Rolf CN, Hellebusch SJ, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction 2002;97:505-516.
43. Shiffman S, Gitchell J, Pinney JM, et al. Public health benefit of over-the-counter nicotine medications. Tob Control 1997;6:306-310.
44. Benowitz NL, Jacob P, III, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 1987;41:467-473.
45. Herrera N, Franco R, Herrera L, et al. O. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 1995;108:447-451.
46. Tonnesen P, Fryd V, Hansen M, et al. Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addict Behav 1988;13:17-27.
47. Russell MAH, Merriman R, Stapleton J, Taylor W. Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking. BMJ 1983;287:1782-1785.
48. Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993;33:23-29.
49. Henningfield JE, Radzius A, Cooper TM. Clayton RR. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA 1990;264:1560-1564.
50. Shiffman S, Shadel WG, Niaura R, et al. Efficacy of acute administration of nicotine gum in relief of cue- provoked cigarette craving. Psychopharmacology 2003;166:343-350.
51. Cohen LM, Collins FL, Brt DM. The effect of chewing gum on tobacco withdrawal. Addict Behav 1997;22:769-773.
52. Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002;162:1267-1276.
53. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003;5:635-644.
54. Molander L, Lunell E, Andersson SB, Kuylenstierna F. Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clin Pharmacol Ther 1996;59:394-400.
55. 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 1995;57:309-317.
56. Lunell E, Molander L, Andersson SB. Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/ in vivo correlation. Eur J Clin Pharmacol 1997;52:495-500.
57. Schneider NG, Lunell E, Olmstead RE, Fagerstrom KO. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 1996;31:65-80.
58. Hurt RD, Offord KP, Croghan IT, et al. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology 1998;140:98-104.
59. Molander L, Lunell E. Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J Clin Pharmacol 2001;56:813-819.
60. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. Transdermal Nicotine Study Group. JAMA 1991;266:3133-3138.
61. Zevin S, Jacob III P, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther 1998; 64:87-95.
62. Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European AntiSmoking Evaluation. European Respiratory Society. Eur Respir J l999;13:238-246.
63. Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995;274:1347-1352.
64. Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation. Nicotine Tob Res 1999;1:169-174.
65. Shiffman S, Paty JA, Gnys M, et al. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 1996;64: 366-379.
66. Cherukuri SR, Pinney JM, Henningfield JE, et al. Medicated chewing gum delivery system for nicotine. Patent No. 6,344,222. Bethesda, MD: JSR, LLC; February 5, 2002.
67. Niaura R, Sayette MA, Shiffman S, et al. Comparative efficacy of rapid-release nicotine gum vs. Nicorette in relieving smoking cue-provoked craving. Presented at: Annual Meeting of the Society for Research on Nicotine and Tobacco; February 19-22, 2003; New Orleans, LA.
68. Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993;33:23-29.
69. Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993;111:271-277.
70. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995;24:41-47.
71. Puska P, Korhonen H, Vartiainen E, et al. Combined use ot nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 1995; 4:231-235.
72. Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 1999;318:285-289.
73. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-691.
74. Shiffman S, Gitchell JG, Warner KE, et al. Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res 2002;4 (Suppl 2):S113-S129.
75. Hall SM, Humfleet GL, Reus VI, et al. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry 2004;161: 2100-2107.
76. Hurt RD, Wolter TD, Rigotti N, et al. Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 2002;27:493-507.
77. Baer JS, Kamarck T, Lichtenstein E, Ransom CC, Jr. Prediction of smoking relapse: analyses of temptations and transgressions after initial cessation. J Consult Clin Psychol 1989;57:623-627.
78. Garvey AJ, Bliss RE, Hitchcock JL, et al. Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addict Behav 1992;17:367-377.
79. Kenford SL, Fiore MC, Jorenby DE, et al. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 1994;271: 589-594.
80. Shiffman S, Scharf D. Milestones in smoking cessation: a process analysis. Presented at: Eighth Annual Meeting of the Society for Research on Nicotine and Tobacco; February 20-23, 2002; Savannah, GA.
81. Balfour DJ, Fagerstrom KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 1996;72:51-81.
82. Hurt R. Clinical Implications of Long-Term Nicotine Use, in Ferrence R, Slade J, Room R, Pope M (eds). Nicotine and Public Health. Washington, DC: American Public Health Association; 2000:389-409.
83. Institute of Medicine. Executive Summary, in Stratton K, Shetty P, Wallace R, Bondurant S (eds). Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington DC: National Academy Press; 2001:1-14.
84. Shiffman S, Gitchell J, Warner KE, et al. Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res 2002;4(suppl 2):S113-S129.
85. Benowitz NL. Compensatory Smoking of Low-Yield Cigarettes, in National Cancer Institute. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2001: 39-63.
86. Hughes JR. Reduced smoking: an introduction and review of the evidence. Addiction 2000; 95(Suppl 1):S3-S7.
87. Fagerstrom KO, Hughes JR. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. Nicotine Tob Res 2002;4(Suppl 2):S73-S79.
88. Lerman C, Niaura R, Collins BN, et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 2004;18:362-366.
89. Cryan JF, Bruijnzeel AW, Skjei KX, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 2003;168:347-358.
90. Bruijnzeel AW, Markou A. Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. SYNAPSE 2003;50:20-28.
91. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 1989; 2:273-279.
92. Nomikos GG, Damsma G. Wenkstern D, Fibiger HC. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 1992;7:7-14.
93. Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction 2004;99:1462-1469.
94. Shiffman S, Johnston JA, Khayrallah M, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 2000; 148:33-40.
95. Henningfield JE, Fant RV, Gopalan L. Non-nicotine medications for smoking cessation. J Respir Dis 1998;19:S33-S42.
96. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004;4;CD000031.
97. Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Prim Care 1999;26:653-669.
98. Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998;158:2035-2039.
99. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998;55:683-689.
100. Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004;164:2229-2233.
101. Edwards NB, Murphy JK, Downs AD, et al. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psychiatry 1989; 146:373-376.
102. Edwards NB, Simmons RC, Rosenthal TL, et al. Doxepin in the treatment of nicotine withdrawal. Psychomatics 1988;29:203-206.
103. Murphy JK, Edwards NB, Downs AD, et al. Effects of doxepin on withdrawal symptoms in smoking cessation. Am J Psychiatry 1990;147: 1353-1357.
104. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 1988;21:253-259.
105. Mayo-Smith MF. Management of alcohol intoxication and withdrawal, in Graham AW, Schultz TK, Wilford BB (eds.). Principles of Addiction Medicine. 2nd ed. Chevy Chase, MD: American Society of Addiction Medicine; 1998:431-440.
106. Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988;259:2863-2866.
107. Black SC. Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004;5: 389-394.
108. Cohen C, Perrault G, Voltz C, et al. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002;13:451-463.
109. Anthenelli R. Smoking cessation in smokers motivated to quit. Presented at: American College of Cardiology Scientific Sessions; March 7-10, 2004; New Orleans, LA.
110. Klesges RC, Winders SE, Meyers AW, et al. How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 1997;65:286-291.
111. Klesges RC, Meyers AW, Klesges LM, La Vasque ME, Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature. Psychol Bull 1989;106: 204-230.
112. Pfizer. Available at: http://www.pfizer. com/pfizer/download/news/ 2005q1_earnq&a. pdf. Accessed September 28, 2004.
113. Cerny T. Anti-nicotine vaccination: where are we? Recent Results Cancer Res 2005;166: 167-175.
114. de Granda Orive JI. When will the nicotine vaccine be ready? Arch Bronconeumol 2005;41: 2-4.
115. Cornuz J, Klingler K, Mueller P, et al. A therapeutic vaccine for nicotine dependence: results of a phase I and a randomized phase II study. Presented at American Society of Clinical Oncology; May 2005; Orlando, FL. Available at: http:// www.asco.org/ac/1.1003,_12-002643-00_18-0034-00_19- 0033424,00.asp. Accessed June 16, 2005.
116. Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000;65:191-198.
117. de Villiers SH, Lindblom N, Kalayanov G, et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002;69: 247-253.
118. Lindblom N, de Villiers SH, Kalayanov G, et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002;69:254-260.
119. Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2004;30:344-345.
120. Royal College of Physicians. Nicotine Addiction In Brain: A Report of the Tobacco Advisory Group of the Royal College of Physicians. London, UK: Royal College of Physicians of London; 2000.
121. Lerman C, Patterson F, Berrettini W. Treating tobacco dependence: state of the science and new directions. J Clin Oncol 2005;23:311-323.
122. Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior, Annu Rev Public Health 2005;26:583-599.
123. Nielsen K, Fiore MC. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. Prev Med 2000;30: 209-216.
124. Henningfield JE. Tobacco dependence treatment: scientific challenges; public health opportunities. Tob Control 2000;9(Suppl 1):I3-I10.
125. Warner KE, Mendez D, Smith DG. The financial implications of coverage of smoking cessation treatment by managed care organizations. Inquiry 2004;41:57-69.